Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 22 Nov 2021 for Acceleron Pharma INC. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Sujay Kango: trading record in brief
Sujay Kango (chief executive) discloses dealings in Acceleron Pharma Inc to SEC (Form 4). In total, 4 filings cover trades dated from 12 February 2021 to 19 November 2021.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 22 November 2021, the filings show a transaction in Acceleron Pharma Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Sujay Kango
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
18,509 sharesCommon StockSEC:0001104659-21-142269:0
5,000 shares@ US$40.6139.2% of flowCommon StockSEC:0001179110-21-008949:0
5,000 shares@ US$40.6139.1% of flowCommon StockSEC:0001179110-21-008894:0
887 shares@ US$130.8721.6% of flowCommon StockSEC:0001179110-21-006494:0
4 of 4 declarations
